The Challenges of Treating Patients with Cancer Pain

References¹

1 R.K. Portenoy, D. Payne and P. Jacobsen, Breakthrough pain: characteristics and impact in patients with cancer pain, Pain 81 (1999), pp. 129–134. Article |

2 T. Gutgsell, D. Walsh, D.S. Zhukovsky, F. Gonzales and R. Lagman, A prospective study of the pathophysiology and clinical characteristics of pain in a palliative medicine population, Am J Hosp Palliat Care 20 (2003), pp. 140–148. View Record in Scopus | Cited By in Scopus (16)

3 S.S. Hwang, V.T. Chang and B. Kasimis, Cancer breakthrough pain characteristics and responses to treatment at a VA medical center, Pain 101 (2003), pp. 55–64. Article |

4 American Pain Foundation, Breakthrough Cancer Pain Survey Fact Sheet http://www.painfoundation.org/learn/programs/spotlight-on-cancer-pain/breakthrough-pain/btcp-fact-sheet.pdf (2009).

5 Actiq (oral transmucosal fentanyl citrate lozenge) prescribing information. Cephalon, Inc. Revised 2007.

6 Fentora (fentanyl buccal tablet) prescribing information. Cephalon, Inc. Revised 2007.

7 , Onsolis (fentanyl buccal soluble film) prescribing information, Meda Pharmaceuticals, Inc (2009).

8 K. Forbes, Opioids: beliefs and myths, J Pain Palliat Care Pharmacother 20 (2006), pp. 33–35. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (8)